Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy (ICC) in previously-treated, inoperable or metastatic hormone-receptor (HR) positive, HER2-negative (HR+/HER2–) breast cancer: TROPION-Breast01 | ANNALS OF ONCOLOGY |